Table 1 Comparison of baseline characteristics in patients categorized by survival and mortality.

From: Changes in acoustic cardiographic parameters before and after hemodialysis are associated with overall and cardiovascular mortality in hemodialysis patients

Characteristics

All patients

(n = 162)

Survival

(n = 137)

Mortality

(n = 25)

p

Age

60.4 ± 10.9

60.0 ± 10.8

62.8 ± 11.0

0.240

Male gender (%)

53.1

53.3

52.0

0.906

Smoking (ever vs. never)

34.6

35.0

32.0

0.769

Diabetes mellitus (%)

46.3

44.5

56.0

0.290

Hypertension (%)

58.6

56.2

72.0

0.140

Coronary artery disease (%)

9.3

10.2

4.0

0.471

Arteriovenous access type (fistula, %)

90.7

92.0

84.0

0.253

Dialysis vintage (years)

9.1 ± 5.9

9.2 ± 5.9

8.6 ± 6.1

0.616

Systolic blood pressure (mmHg)

157.0 ± 23.3

157.7 ± 23.7

153.5 ± 21.1

0.407

Diastolic blood pressure (mmHg)

81.8 ± 13.5

82.2 ± 13.8

79.2 ± 11.9

0.303

Laboratory parameters

    

Albumin (g/dL)

3.9 ± 0.3

3.9 ± 0.3

3.7 ± 0.5

0.018

Triglyceride (mg/dL)

114 (85–181)

121.5 (86.5–182.25)

101 (73–156.5)

0.560

Total cholesterol (mg/dL)

173.1 ± 41.7

175.3 ± 40.7

161.4 ± 45.7

0.126

Hemoglobin (g/dL)

10.5 ± 1.3

10.6 ± 1.3

10.1 ± 1.3

0.057

Total calcium (mg/dL)

9.4 ± 0.9

9.4 ± 0.9

9.4 ± 0.7

0.811

Phosphorous (mg/dL)

4.6 ± 1.0

4.6 ± 1.0

4.5 ± 1.0

0.596

CaXP product (mg2/dL2)

43.8 ± 9.9

44.0 ± 10.0

42.6 ± 9.2

0.542

Potassium (mEq/L)

4.8 ± 0.6

4.9 ± 0.7

4.7 ± 0.6

0.160

Uric acid (mg/dL)

7.3 ± 1.4

7.3 ± 1.4

7.1 ± 1.5

0.489

Kt/V (Daugirdas)

1.69 ± 0.27

1.68 ± 0.27

1.75 ± 0.29

0.281

Blood flow (ml/min)

279.6 ± 20.1

279.8 ± 19.9

278.4 ± 21.7

0.754

Medications

    

ACEI and/or ARB use (%)

26.5

25.5

32.0

0.502

β-blocker use (%)

23.5

22.6

28.0

0.560

Statin use (%)

22.8

22.6

24.0

0.881

Aspirin use (%)

17.3

17.5

16.0

1.000

ACP before hemodialysis and ACP

 Heart rate (beats/min)

79.2 ± 12.0

79.2 ± 12.0

78.7 ± 12.3

0.844

Heart rate (beats/min)

− 3.2 ± 0.9

− 4.0 ± 1.0

1.5 ± 2.1

0.033

 QRS Duration (ms)

103.5 ± 30.9

103.0 ± 30.4

106.3 ± 33.9

0.630

QRS Duration (ms)

1.4 ± 2.7

1.4 ± 2.9

1.1 ± 7.9

0.966

 QTc (ms)

420.1 ± 37.5

419.1 ± 38.3

425.8 ± 32.9

0.415

QTc (ms)

− 3.8 ± 4.6

− 5.9 ± 5.0

8.2 ± 10.5

0.269

 PR interval (ms)

171.2 ± 34.6

170.3 ± 33.5

176.1 ± 40.2

0.459

PR interval (ms)

− 9.2 ± 3.7

− 3.6 ± 3.4

− 34.9 ± 11.6

0.017

 S3

2.8 ± 1.3

2.8 ± 1.3

2.7 ± 1.1

0.862

S3

− 0.09 ± 0.11

− 0.10 ± 0.12

− 0.02 ± 0.31

0.788

 S4

4.9 ± 2.0

4.9 ± 2.0

4.8 ± 1.8

0.889

S4

− 1.0 ± 0.2

− 1.0 ± 0.2

− 1.3 ± 0.4

0.468

 SDI

3.7 ± 1.6

3.7 ± 1.5

3.8 ± 2.0

0.816

SDI

0.071 ± 0.123

0.001 ± 0.122

0.460 ± 0.433

0.180

 EMAT (ms)

90.9 ± 15.7

91.2 ± 14.8

89.3 ± 20.0

0.580

EMAT (ms)

4.4 ± 1.2

4.4 ± 1.3

4.4 ± 3.8

0.999

 EMAT (%)

11.4 ± 2.8

11.5 ± 2.8

11.1 ± 2.9

0.485

EMAT (%)

0.08 ± 0.23

− 0.05 ± 0.26

0.85 ± 0.59

0.167

 LVST (ms)

331.8 ± 37.5

331.8 ± 37.7

331.7 ± 37.2

0.988

LVST (ms)

− 11.9 ± 3.9

− 7.8 ± 3.6

− 34.9 ± 15.0

0.012

 LVST (%)

42.4 ± 4.6

42.4 ± 4.6

42.4 ± 5.1

0.975

LVST (%)

− 2.9 ± 0.4

− 3.0 ± 0.4

− 2.0 ± 1.2

0.400

  1. Abbreviation: CaXP product, calcium × phosphorus product; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ACP, acoustic cardiography parameters; SDI, Systolic dysfunction index; EMAT, Electromechanical activation time; LVST, LV systolic time.